Call Us Contact Us
+44 1494 818 000     Online Enquiry
Lines open
Monday to Thursday
08:30 to 18:00
Friday
08:30 to 17:30
Pharmaceutical | Medical Devices | Scientific | Consumer Healthcare | Dental | Animal Health | FMCG | Executive
         
Latest Jobs

South West
24 May 2013 17:14



North East London
24 May 2013 16:39



South and South West
24 May 2013 16:16


Have you registered?
Once you register you can see additional job details, save jobs, track your applications and manage e-lert preferences.

Register now
Testimonials
Zenopa keeps things professionally simple. Form the commitment to work with and help you to gain a position through to working for them as a contractor.
Angela, 2012

Eli Lilly drug Prozac 'could treat lazy eye'

18 April 2008 00:00 in Pharmaceutical Company Product News


The success of Eli Lilly's depression drug Prozac in correcting the eyesight of rats could point the way to correcting amblyopia, or lazy eye, in human adults, researchers suggests.

Researchers from Scuola Normale Superiore in Pisa also said its research into rats whose eyesight had been impaired during development could show how Prozac works to alleviate depression.

They said the Eli Lilly drug, also known as fluoxetine, appeared to return neurons to a more flexible state that allowed the visual perception system to develop proper connections.

This "brain plasticity" could also be how the drug improves patient depression, they stated with their findings, which were published in the journal Science.

Prozac was first introduced by Eli Lilly in 1987 and is known as a selective serotonin reuptake inhibitor (SSRI). Following the end of its patent it is also available generically.

Lead scientist Dr Jose Fernando Maya and his colleagues wrote: "Our results suggest a potential clinical application for fluoxetine in amblyopia."

As well as a tablet, Prozac is also available as a liquid.

Other news stories from 18/04/2008

Recent news

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Adfero News Agency



   
© Copyright 2013 Zenopa Ltd